{"id":"NCT00871494","sponsor":"Pfizer","briefTitle":"Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan","officialTitle":"A Multicenter, Non-Randomized, Open Label Study Of Azithromycin Intravenous Followed By Oral Administration In Japanese Adult Subjects With Pelvic Inflammatory Disease (PID) Requiring Initial Intravenous Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-05","primaryCompletion":"2010-11","completion":"2010-11","firstPosted":"2009-03-30","resultsPosted":"2011-11-03","lastUpdate":"2011-11-03"},"enrollment":76,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pelvic Inflammatory Disease"],"interventions":[{"type":"DRUG","name":"Azithromycin","otherNames":[]}],"arms":[{"label":"Azithromycin switch therapy (switch from intravenous to oral).","type":"EXPERIMENTAL"}],"summary":"Azithromycin had a potent in vitro activities and broad spectrum from typical and atypical bacteria to anaerobes. Azithromycin intravenous formulation demonstrated high efficacy and eradication rate in the western clinical trials. Development of azithromycin intravenous formulation would bring the clinical benefit to patients with pelvic inflammatory disease (PID) in Japan.","primaryOutcome":{"measure":"Response Rate (Clinical Response, Data Review Committee Assessment) in Participants Who Enrolled After Protocol Amendment (the Inclusion Criterion Regarding Fever of 37â„ƒ or Higher Was Option)","timeFrame":"End of Treatment, Day 15 and Day 29","effectByArm":[{"arm":"Azithromycin","deltaMin":94.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":null},"locations":{"siteCount":31,"countries":["Japan"]},"refs":{"pmids":["24787738"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0661192&StudyName=Study%20Of%20Azithromycin%20Intravenous%20Formulation%20Against%20Pelvic%20Inflammatory%20Disease%20%28PID%29%20In%20Japan"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":76},"commonTop":["Diarrhoea","Injection site pain","Nausea","Nasopharyngitis","Abdominal tenderness"]}}